Geriatric Medicines Market Report 2026

The geriatric medicines market size has grown rapidly in recent years. It will grow from $1.42 trillion in 2025 to $1.65 trillion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to aging population growth, rise in chronic diseases, expansion of hospital pharmacies, early geriatric drug development, increased life expectancy.

The geriatric medicines market size is expected to see rapid growth in the next few years. It will grow to $2.97 trillion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to growth in elderly population, development of safer formulations, expansion of online pharmacies, focus on personalized geriatric care, rising healthcare expenditure. Major trends in the forecast period include growing demand for polypharmacy management, increased focus on age-specific drug formulations, rising use of cognitive health medications, expansion of chronic disease drug therapies, improved medication adherence solutions.

The rising prevalence of age-related health conditions is expected to drive the growth of the geriatric medicines market in the coming years. Age-related health conditions are medical issues that become more frequent or severe with advancing age due to the natural aging process. Factors such as longer life expectancy, advancements in healthcare, and an aging population contribute to the increasing incidence of these conditions. Geriatric medicines help manage age-related health issues by providing specialized treatments for older adults, improving their quality of life and health outcomes. For example, in April 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that in 2023, approximately 194 million American adults - 6 in 10 young adults, 8 in 10 midlife adults, and 9 in 10 older adults - had one or more chronic conditions. Among young adults, the prevalence of chronic conditions increased by 7 percentage points. Consequently, the growing prevalence of age-related health conditions is fueling the geriatric medicines market.

Key companies in the geriatric medicines market are developing innovative diabetes therapies to meet the rising demand for effective solutions among the aging population. Diabetes therapy involves advanced treatments that improve management or provide better outcomes compared to traditional approaches, enhancing efficacy, safety, and patient well-being. For instance, in August 2023, Akums Drugs & Pharmaceuticals Ltd., an India-based contract manufacturing pharmaceutical company, launched a novel combination therapy containing Vildagliptin SR and Metformin SR. This formulation is specifically designed for managing Type 2 diabetes in elderly patients, providing effective glycemic control while minimizing risks such as hypoglycemia and weight gain, which are critical for this demographic. By combining the mechanisms of both drugs, the therapy enhances insulin secretion and lowers blood sugar levels safely and effectively. The product has received approval from the Drug Controller General of India (DCGI).

In October 2023, Zydus Pharmaceuticals UK Limited, a UK-based pharmaceutical company, acquired LiqMeds Group for an undisclosed amount. Through this acquisition, Zydus Life Sciences aims to expand its presence in the growing oral liquid products market, addressing the unmet needs of geriatric and pediatric patients. LiqMeds Group is a UK-based pharmaceutical company specializing in oral liquid formulations that are particularly beneficial for elderly patients.

Major companies operating in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Endo Pharmaceuticals Inc.

North America was the largest region in the geriatric medicines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the geriatric medicines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the geriatric medicines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the geriatric medicines market by increasing costs of imported active pharmaceutical ingredients, finished formulations, and specialty drugs. Hospital and retail pharmacies in developed regions are most affected due to reliance on imported medicines. These tariffs raise treatment costs but encourage domestic pharmaceutical manufacturing for elderly care.

The geriatric medicines market research report is one of a series of new reports that provides geriatric medicines market statistics, including geriatric medicines industry global market size, regional shares, competitors with a geriatric medicines market share, detailed geriatric medicines market segments, market trends and opportunities, and any further data you may need to thrive in the geriatric medicines industry. This geriatric medicines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Geriatric medicines are drugs prescribed for individuals aged 65 and older, targeting the specific health requirements of the elderly. They are formulated to support cognitive function, mobility, and immune health while accounting for age-related physiological changes that affect drug metabolism. These medications help manage chronic conditions and age-related symptoms, improving overall quality of life.

The primary therapeutics in geriatric medicines include analgesics, antihypertensives, statins, proton pump inhibitors, anticoagulants, antipsychotics, and others. Analgesics play a key role in geriatric care by managing chronic pain, enhancing mobility, and improving quality of life for older adults. They are used to treat various conditions, including cardiovascular diseases, arthritis, neurological disorders, cancer, osteoporosis, respiratory conditions, and more. These medications are administered through multiple routes, such as oral and parenteral, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

The geriatric medicines market consists of sales of antidepressants, diuretics, antidiabetics, and anticonvulsants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.